Qiagen N.V. is a prominent provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. Operating within the Healthcare sector, specifically in the Diagnostics & Research industry, the company holds a market capitalization of 8.42 Billion. The stock has recently experienced downward pressure, with a 7-day change of -3.95% and a current price of approximately EUR38.35.

Based on our technical scoring system, Qiagen N.V. currently receives a "Sell" rating with a total score of -3. The primary driver for this negative outlook is the trend indicator, which scores -2 as the price is trading below its 200-day simple moving average (SMA). This suggests a prevailing bearish long-term trend. This weakness is further confirmed by bearish signals from momentum and volume indicators. The MACD histogram is negative (Score: -1), indicating ongoing downward momentum, and the On-Balance Volume (OBV) is below its short-term average (Score: -1), signaling distribution or selling pressure. The ADX indicator is below 25, suggesting the current trend is not yet considered strong.

The technical "Sell" rating presents a conflict with some of the company's fundamental and earnings data. While the P/E ratio of 24.27 is reasonable for its industry, the most notable factor is its last earnings report. Qiagen reported an EPS of 0.34, which represented a massive positive surprise of 92.0%. This strong performance highlights operational health that isn't currently reflected in the stock's technical posture. Investors should therefore be cautious: while technical indicators point to continued weakness, the strong underlying earnings could provide a catalyst for a reversal if market sentiment shifts. The next earnings report is scheduled for 04/02/2026.